The stock of Iovance Biotherapeutics Inc (IOVA) has seen a 11.39% increase in the past week, with a 31.74% gain in the past month, and a -27.51% decrease in the past quarter. The volatility ratio for the week is 8.01%, and the volatility levels for the past 30 days are at 8.14% for IOVA. The simple moving average for the last 20 days is 11.96% for IOVA’s stock, with a simple moving average of -31.06% for the last 200 days.

Is It Worth Investing in Iovance Biotherapeutics Inc (NASDAQ: IOVA) Right Now?

, and the 36-month beta value for IOVA is at 0.19. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”

The average price suggested by analysts for IOVA is $21.18, which is $16.78 above the current market price. The public float for IOVA is 198.22M, and currently, shorts hold a 19.61% of that float. The average trading volume for IOVA on November 17, 2023 was 6.41M shares.

IOVA) stock’s latest price update

Iovance Biotherapeutics Inc (NASDAQ: IOVA)’s stock price has dropped by -7.37 in relation to previous closing price of 4.75. Nevertheless, the company has seen a gain of 11.39% in its stock price over the last five trading days. The Motley Fool reported 2023-11-08 that Biotech stocks are slumping yet again today. However, Iovance Biotherapeutics is swimming against the current thanks to excitement over its adoptive cell therapy.

Analysts’ Opinion of IOVA

Many brokerage firms have already submitted their reports for IOVA stocks, with Barclays repeating the rating for IOVA by listing it as a “Overweight.” The predicted price for IOVA in the upcoming period, according to Barclays is $18 based on the research report published on September 18, 2023 of the current year 2023.

IOVA Trading at 1.08% from the 50-Day Moving Average

After a stumble in the market that brought IOVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.99% of loss for the given period.

Volatility was left at 8.14%, however, over the last 30 days, the volatility rate increased by 8.01%, as shares surge +33.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.14% lower at present.

During the last 5 trading sessions, IOVA rose by +11.39%, which changed the moving average for the period of 200-days by -44.37% in comparison to the 20-day moving average, which settled at $3.99. In addition, Iovance Biotherapeutics Inc saw -31.14% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at IOVA starting from MCPEAK MERRILL A, who purchase 10,000 shares at the price of $5.56 back on Sep 18. After this action, MCPEAK MERRILL A now owns 248,633 shares of Iovance Biotherapeutics Inc, valued at $55,600 using the latest closing price.

Rothbaum Wayne P., the Director of Iovance Biotherapeutics Inc, purchase 5,000,000 shares at $5.30 during a trade that took place back on Sep 15, which means that Rothbaum Wayne P. is holding 23,067,333 shares at $26,500,000 based on the most recent closing price.

Stock Fundamentals for IOVA

Equity return is now at value -81.10, with -61.93 for asset returns.


In conclusion, Iovance Biotherapeutics Inc (IOVA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.